Who Generates More Revenue? TG Therapeutics, Inc. or Celldex Therapeutics, Inc.

Biotech Revenue Battle: TG vs. Celldex

__timestampCelldex Therapeutics, Inc.TG Therapeutics, Inc.
Wednesday, January 1, 20143586000152381
Thursday, January 1, 20155480000152381
Friday, January 1, 20166786000152381
Sunday, January 1, 201712743000152381
Monday, January 1, 20189538000152000
Tuesday, January 1, 20193573000152000
Wednesday, January 1, 20207418000152000
Friday, January 1, 202146510006689000
Saturday, January 1, 202223570002785000
Sunday, January 1, 20236883000233662000
Loading chart...

Unleashing insights

Revenue Race: TG Therapeutics vs. Celldex Therapeutics

In the competitive landscape of biotechnology, revenue generation is a key indicator of a company's market position and potential for growth. Over the past decade, TG Therapeutics, Inc. and Celldex Therapeutics, Inc. have been vying for dominance. From 2014 to 2023, Celldex's revenue fluctuated, peaking in 2017 with a 100% increase from 2014. However, TG Therapeutics made a dramatic leap in 2023, with revenue skyrocketing by over 100,000% compared to its 2014 figures. This surge highlights TG Therapeutics' strategic advancements and market penetration. While Celldex maintained a steady revenue stream, TG Therapeutics' recent performance suggests a significant shift in the biotech revenue landscape. As the industry evolves, these companies' financial trajectories will be crucial for investors and stakeholders to watch.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025